Cancer research

Golcadomide in B-Cell Lymphoma

Dec 15, 2023

Harmony in Treatment: GOLCA (golcadomide) Reveals Favorable Safety Profile and Seamless Integration with R-CHOP for Untreated Aggressive B-Cell Lymphoma

ALLO-647 for Lymphodepletion

Dec 15, 2023

ALLO-647 Integration in Lymphodepletion: Paving the Way for Enduring Responses and Safe CAR T cell Therapy Advancements

Golcadomide-Rituximab Combo in DLBCL Patient

Dec 15, 2023

Golcadomide and Rituximab Combo Unveils Promising Efficacy in Heavily Pretreated Relapsed/Refractory DLBCL

ZYNLONTA-Rituximab Combo in Follicular Lymphoma

Dec 15, 2023

Pioneering Progress: ZYNLONTA and Rituximab Combo Delivers Striking 96% Overall Response in Relapsed Follicular Lymphoma

Dec 15, 2023

Breaking Ground: Ibrutinib and Venetoclax Synergy Delivers Significant Progression-Free Survival Boost in Relapsed/Refractory Mantle Cell Lymphoma

Phase 1 trial of Bgb-16673

Dec 15, 2023

BGB-16673 Breakthrough: A Tolerable Triumph in Rapid Clinical Responses for Relapsed/Refractory B-Cell Malignancies

Phase 1b MonumenTAL-2 Study Result

Dec 14, 2023

TALVEY’s Versatility Shines: Key Insights from MonumenTAL-2 Study Illuminate Effective Strategies in Relapsed/Refractory Multiple Myeloma

Dec 14, 2023

Breakthrough Success: AUGMENT-101 Trial Hits Primary Endpoint with Consistent CR/CRh Rates Across Adult and Pediatric KMT2Ar AML and ALL Cohorts

Phase 3 Results Support D-VRd

Dec 13, 2023

DARZALEX FASPRO Quadruplet Regimen Demonstrates Striking Advancements in Treatment Outcomes for Newly Diagnosed Multiple Myeloma Eligible for Transplantation

Phase 3 CARTITUDE-4 Study

Dec 13, 2023

Cilta-cel Demonstrates Prolonged and Deep Responses across Advanced Treatment Lines, Signifying Potential in Early Lenalidomide-Refractory Multiple Myeloma

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper